NY-AQARA
27.4.2022 09:02:04 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the launch of its new Motion Sensor P1, an updated model of the best-selling Aqara Motion Sensor. The sensor is a PIR motion and motion-light sensor that detects motion as well as the ambient light status in the room, and can be used for home security and automation. Built on the previous generation, the P1 model further extends the battery life to a record length of up to 5 years*, thanks to more power-efficient technologies and the improved batteries. The new sensor has been made available on Amazon in the US , Canada , Germany and France , as well as via selective Aqara retailers in North America, Europe, Asia and Oceania**. It is expected to hit Amazon UK in the following weeks.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability and better compatibility, the Motion Sensor P1 adds more flexibility for users including a configurable detection timeout and the adjustable sensitivity level. No longer fixed at a 60-second timeout like the predecessor, the P1 sensor allows users to set the detection timeout between 1 to 200 seconds on the Aqara Home app. It’s also possible to set the sensitivity level to high, medium or low, which refers to the distance from which the sensor will be triggered from, so that false alarms could be reduced. By default which is medium sensitivity, the sensor supports a field of view (FoV) of 170° for up to 2 meters and 150° for up to 7 meters.
The P1 motion sensor are compatible with major smart home ecosystems including HomeKit, Alexa, IFTTT and more. Moreover, the sensor will support Matter - the new connectivity standard for IoT devices - via an OTA update of Aqara hubs after the Matter rollout. The sensor itself also supports OTA updates, which means that new features and fixes now can be added after the release of the product.
Motion sensor has become increasingly popular among smart home users, as it is a natural part of the majority of smart home automations. The combination of an Aqara hub, a Motion Sensor P1 and controller devices like smart wall switches and roller shade drivers can automate many routine tasks, such as turning on the lights, opening the sun shades or controlling the TV. Moreover, with P1’s built-in light sensor, the lights could be controlled more precisely. For example, users could set to turn on the hallway lights only when it’s dark and motion is detected, so that energy consumption is reduced, and the lifespan of lights is increased.
To celebrate the launch, Aqara now offers a 10% discount for the new Motion Sensor P1 on its Amazon brand stores. North American customers will enjoy the offer with the promo code MOTIONUS in the US and Canada , while European customers will enjoy it using the promo code EUMOTIONPI in Germany and France . Both codes will be valid through April 29, 2022.
For more details of the Motion Sensor P1, please visit our website .
* Based on lab test, on the assumption of LED trigger indicator disabled and detection timeout of no less than 30 seconds.
** Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release
New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
